版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Therapy of Malignant Pheochromocytoma恶性嗜铬细胞瘤的治疗,Literature Report,26.01.2021,2,Introduction,rule of 10s for pheochromocytoma (PCC) 10% bilateral 10% extra-adrenal 10% extra-abdomen 10% malignant 10% familial 10% children 10% normal blood pressure,26.01.2021,3,Introduction,The most frequent site of m
2、etastases is the skeleton Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney,26.01.2021,4,Malignant vs. Benign,Currently, there is no effective cure for malignant pheochromocytoma. There are also no reliable histopathological methods for distinguishing benign from
3、malignant tumors. Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor,26.01.2021,5,Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usua
4、lly within 5 years, but sometimes 16 or more years later,26.01.2021,6,Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results,26.01.2021,7,Because there is currently no effecti
5、ve cure for malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival. Without treatment, the 5-year survival is generally less than 50%. The course, however, can be highly variable with occasional patients living more than 20 years aft
6、er diagnosis,26.01.2021,8,Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking,26.01.2021,9,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,26.01.2021,10,Alternative of
7、Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,26.01.2021,11,Primary surgical resection is the treatment of choice whenever possible Limited disease: curative intention Extended disease: still to be considered in the first place for debulking and as palliati
8、ve treatment (Mundschenk et al. 1998,26.01.2021,12,Problem,When signs of regional involvement or distant disease are absent, there is currently no reliable preoperative diagnostic test that can differentiate between malignant and benign pheochromocytomas Should pheochromocytoma size influence surgic
9、al approach,26.01.2021,13,A comparison of 90 malignant and 60 benign pheochromocytomas (Wen T. Shen et al.2004) Comparison of tumor size for benign pheochromocytomas and malignant pheochromocytomas with local disease only Size does not reliably predict malignancy in pheochromocytomas with local dise
10、ase only,26.01.2021,14,26.01.2021,15,Malignant PCCs presenting with only local disease cannot be discriminated from benign PCCs by size alone. When PCCs do not have evidence of invasion or distant metastases and the surgeon acquires an appropriate level of experience, the majority of these tumors ca
11、n be safely resected laparoscopically,26.01.2021,16,Laparoscopic adrenalectomy for pheochromocytoma should be converted to open adrenalectomy for difficult dissection, invasion, adhesions, or surgeon inexperience,26.01.2021,17,Surgical approach,Transabdominal approach is necessary minimally invasive
12、 procedures retroperitoneal approaches should be abandoned to definitely preserve the tumor capsule and perform total lymphadecectomy (Orchard et al. 1993,26.01.2021,18,Secondary Tumors,No experience with adjuvant pre and postoperative radiation exists Generally are multiple Radical surgical resecti
13、on is often impossible Other treatment modalities have to be considered,26.01.2021,19,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,26.01.2021,20,26.01.2021,21,131I-MIBG is the treatment of choice for all unresectable, MIBG positive tumors 58
14、 cases of malignant PCC treated by 131I-MIBGtherapeutic results and adverse events (ZHU Ruisen et al. 1999,26.01.2021,22,Patients were classified into 3 groups according to their tumor size 20 cm3 (26 cases) In group 1, the mean absorption dose per gram of tumor was above 1 000 cGy. After treatment
15、,tumors disappeared or shrinked in all patients,26.01.2021,23,In group 2 , the absorption dose was similar to that of group 1, but the mean absorption dose per gram was 717.6 cGy , and tumor mass regression was 36 % ;76 % reduced urinary catecholamine In group 3 , the absorption dose per gram tumor
16、tissue was 277 cGy , and 30 % tumor enlargement , 20 % died ; the remaining 50 % symptomatic improvement without any change in tumor size,26.01.2021,24,131 I-MIBG is of certain therapeutic effectiveness of symptomatic improvement Complete tumor mass disappearance has only been found in small tumors
17、Treatment with 131 I-MIBG should be instituted immediately after surgical resection to eradicate the residual tumor cells and to prevent recurrences Bone marrow suppression is temporary and not dosage related,26.01.2021,25,In 1997, Loh et al. published a review of the worldwide experience involving
18、116 patients treated with 131I-MIBG for malignant pheochromocytoma. Overall, there was a symptomatic response in 76%, a hormonal response in 45%, and tumor regression in 30%. The activity of 131I-MIBG per single dose was 96300 mCi, and the mean cumulative activity was 490350 mCi. Only five CRs to 13
19、1I-MIBG were reported,26.01.2021,26,Limitations,Not all patients with multiple metastases of malignant pheochromocytomas have sufficient uptake of MIBG to allow MIBG therapy MIBG negative lesions coexist with MIBG postive lesions, requiring combined treatment,26.01.2021,27,As a single agent,131I-MIB
20、G has limited efficacy in treating malignant pheochromocytoma. Its use in combination with other cytotoxic agents, as is currently being studied in patients with neuroblastoma, may result in additional benefit (Sisson et al. 1999,26.01.2021,28,Alternative of Current Therapy,Surgery Radiopharmaceutic
21、als Combined Chemotherapy Arterial Embolization,26.01.2021,29,Only sparse data on chemotherapeutic regimens are available, most of them in reports of few cases The most well-established regimen is CVD (Averbuch et al. 1988) CTX 750mg/m2 d1, VCR 1.4mg/m2 d1, Dacarbazine 600mg/m2 d1,2 Cycle 21 days,26.01.2021,30,The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in ma
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 《 M通信公司工程建设物资物流运营体系优化研究》范文
- 多发伤骨折护理查房
- 《 焊接工艺参数对三种管线钢焊接热影响区组织及韧性的影响》范文
- 毛皮服装行业区块链技术在供应链中的应用考核试卷
- 噪声与振动控制中的噪声控制设施维护考核试卷
- 毛皮行业政策环境分析考核试卷
- 针织品市场细分与定位考核试卷
- 中盐宁夏盐业有限公司招聘笔试题库2024
- 铅锌矿选矿厂资源节约与循环利用考核试卷
- 南充环境集团有限责任公司招聘笔试题库2024
- GB/T 42716-2023电化学储能电站建模导则
- IFS ERP、EAM系统功能清单
- 北师大版八年级数学上章节目标及课标要求
- 【高中物理】分子动能和分子势能 课件 2022-2023学年高二下学期物理人教版(2019)选择性必修第三册
- 药物临床试验质量管理规范2022版
- 小学“小科学家”评选活动方案
- 税务培训股权转让个人所得税
- 电子游戏发展史
- 石膏固定术课件
- 四巧板(T字之谜)505图答案
- 2013年专八真题及答案
评论
0/150
提交评论